N,N-dimethyltryptamine — Schedule I federally; decriminalized in Colorado; the active compound in ayahuasca.
N,N-dimethyltryptamine — commonly called DMT — is a tryptamine alkaloid found in dozens of plant species and produced in trace amounts by the human body. It is a potent 5-HT2A serotonin receptor agonist, the same mechanism shared by psilocybin, LSD, and mescaline, which is why all four are classified as "classic psychedelics."
DMT is the primary psychoactive compound in ayahuasca — the Amazonian brew that combines a DMT-containing plant (Psychotria viridis or Diplopterys cabrerana) with a monoamine oxidase inhibitor (MAOI) vine (Banisteriopsis caapi). The MAOI is essential: oral DMT is rapidly broken down by gut and liver MAO enzymes unless an inhibitor is present. When inhaled or injected without an MAOI, DMT produces a radically different — and dramatically shorter — experience.
DMT is distinct from 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), a related but pharmacologically different compound found in the Sonoran Desert toad. 5-MeO-DMT is primarily a 5-HT1A agonist and produces a different subjective experience. Both are Schedule I. For a full breakdown, see our 5-MeO-DMT vs DMT comparison.
N,N-DMT has the molecular formula C12H16N2 and a molecular weight of 188.27 g/mol. Its structure is a tryptamine backbone — an indole ring system with a two-carbon ethylamine side chain — with two methyl groups attached to the terminal nitrogen. This basic tryptamine scaffold is shared by psilocin (the active form of psilocybin), serotonin itself, and melatonin, which is why DMT’s endogenous presence in the human body has been a recurrent point of legal argument.
The DEA classified DMT under Schedule I in 1970 on the grounds that it has “no currently accepted medical use” and a “high potential for abuse” — criteria that critics argue were applied before meaningful clinical research existed. Unlike psilocybin and LSD, which accumulated some pre-1970 clinical literature, DMT entered scheduling primarily on the basis of its structural similarity to other controlled tryptamines and its use in the counterculture.
The structural relationship between DMT and serotonin creates a pharmacological paradox at the center of DMT’s legal status: the compound that the federal government classifies as having “no medical use” activates the same receptor system (5-HT2A) that is the primary target of the FDA’s most rapidly advancing psychiatric drug class (the psychedelic-assisted therapies in Phase 3 trials). Small Pharma’s SPL026 program — IV DMT infusion for treatment-resistant depression — reached Phase 2b before the company was acquired, and the compound’s rapid clearance makes precise dose control feasible in a clinical setting.
The DMT experience is consistently described as one of the most intense altered states a human being can undergo — and one of the shortest when smoked. Users commonly report complete dissolution of the ordinary sense of self and environment, contact with geometric visual patterns or perceived entities, and a sense of entering an entirely different realm. The content varies widely by individual, dose, and route. Unlike most psychedelics, the smoked DMT experience offers almost no time to orient before reaching full effect.
At the federal level: no. N,N-DMT has been classified as a Schedule I controlled substance under the Controlled Substances Act since the law was enacted in 1970. Schedule I means the federal government has determined that it has no currently accepted medical use and a high potential for abuse. Possession or distribution carries felony penalties under 21 U.S.C. § 844 and § 841.
The fact that DMT is produced endogenously in trace amounts by the human body has been raised as a legal defense in several cases. The DEA has formally stated this does not affect scheduling, and no court has accepted the argument as a basis for dismissal.
| State | DMT status | Notes |
|---|---|---|
| Colorado | Personal use decriminalized (21+) | Prop 122 (2022) included DMT in natural medicines decriminalization. Possession for personal use is a civil matter, not a crime. DMT healing centers have not been licensed yet — the Advisory Board is expected to address DMT in its 2026 regulatory cycle. Colorado is the only US state with any DMT-specific decriminalization. |
| Oregon | Schedule I — not included in Measure 109 | Oregon's Measure 109 (2020) only covers psilocybin services. DMT is not included in the licensed program. Measure 110's broad decriminalization was partially rolled back by HB 4002 (2024) and does not specifically protect DMT. |
| California | Schedule I under state law | DMT is Schedule I under California Health & Safety Code §11054. Six cities (Oakland, San Francisco, Santa Cruz, Berkeley, Arcata, Eureka) have passed deprioritization resolutions for entheogenic plants and fungi — these are not legal protections and do not bind state or federal prosecutors. SB 751 (2025) advancing in Sacramento could change the landscape. |
| Washington | Schedule I | No state-level DMT decriminalization. Cities of Seattle, Port Townsend, and Olympia have deprioritization resolutions for entheogens generally. |
| Texas, Illinois, Michigan, Ohio, Oklahoma, Florida, Arizona, Connecticut, Hawaii, Kansas, Kentucky, Louisiana, Maryland, Missouri, Massachusetts, Minnesota, Montana, Mississippi, New Mexico, New York, Pennsylvania, Tennessee, Utah, Virginia, West Virginia, Wyoming | Schedule I under both federal and state law | No DMT-specific decriminalization, exemption, or city resolution exists in any of these states as of 2026. DMT possession, sale, or distribution carries the same criminal exposure as federal law. (Colorado remains the sole exception above.) |
| All other states | Schedule I | No state has legalized or decriminalized standalone DMT (outside of the ayahuasca/religious-exemption context). |
Search interest often bundles "is DMT legal to buy," "sell," "take," and "possess" together, but the law treats them very differently — and this distinction holds regardless of state. Under federal law, personal possession is a misdemeanor for a first offense (up to one year in federal prison under 21 U.S.C. § 844), while buying, selling, manufacturing, or distributing DMT is prosecuted as trafficking — a felony under 21 U.S.C. § 841 carrying up to 20 years in federal prison, even for a first offense and even in small quantities. Even in Colorado, where personal possession is decriminalized under Prop 122, sale and distribution of DMT remain illegal; the decriminalization covers possession only. See "What are the federal penalties for DMT possession?" below for the full breakdown.
No. DMT is Schedule I under California Health & Safety Code §11054, mirroring its federal classification. Possession, sale, or distribution is a criminal offense under state law. Six California cities — Oakland, San Francisco, Santa Cruz, Berkeley, Arcata, and Eureka — have passed city council resolutions directing police to make enforcement of entheogenic plant and fungi laws the lowest priority. These resolutions do not make DMT legal; they only affect local police enforcement priorities. State and federal prosecutors are not bound by city resolutions.
California's SB 751 (2025), advancing through the state senate as of early 2026, would create a regulated therapeutic access framework for certain plant medicines. Whether DMT would be explicitly included remains to be seen; the bill's trajectory and final language should be checked for the most current status.
Under the Religious Freedom Restoration Act (RFRA), religious organizations can petition for an exemption to the Controlled Substances Act when sincerely held religious beliefs require the use of a controlled substance. Four organizations currently hold confirmed DEA exemptions to use DMT-containing ayahuasca:
4-AcO-DMT (4-acetoxy-N,N-dimethyltryptamine, also called O-acetylpsilocin or psilacetin) is a synthetic tryptamine that is metabolized in the body to psilocin — the same active metabolite produced by psilocybin mushrooms. The compound was first synthesized by Albert Hofmann and Franz Troxler in 1963.
Is 4-AcO-DMT on the DEA Schedule I list? As of 2026, 4-AcO-DMT is not explicitly enumerated in the DEA's Schedule I drug list. This has made it a popular "research chemical," sold online with "not for human consumption" disclaimers. However, the legal picture is not simple:
DMT is illegal in most of the world. Every country that signed the 1971 UN Convention on Psychotropic Substances has DMT scheduled at the strictest tier. But several countries treat ayahuasca differently, and a handful have decriminalized personal possession.
For the full country-by-country breakdown including legal retreat jurisdictions, religious exemption rules, and ayahuasca-specific carve-outs, see our dedicated Where Is DMT Legal? US & international guide.
N,N-DMT has a smaller clinical research pipeline than psilocybin or MDMA, but serious work has been done and is continuing:
The first systematic human research on intravenous DMT in the modern era was conducted by psychiatrist Rick Strassman at the University of New Mexico under a DEA Schedule I researcher license and FDA IND. Strassman administered IV DMT to 60 human volunteers across approximately 400 sessions, studying dose-response, subjective effects, and autonomic/neuroendocrine changes.1 This work, summarized in his 2001 book DMT: The Spirit Molecule, laid the pharmacological foundation for subsequent clinical interest.
London-based Small Pharma developed SPL026, an intravenous N,N-DMT fumarate formulation for major depressive disorder. Cybin acquired Small Pharma in 2023, then rebranded to Helus Pharma in early 2026. The Phase 2a trial (NCT04673383) met its primary endpoint: SPL026 with supportive therapy produced a statistically significant 7.4-point reduction in MADRS depression scores versus placebo at 2 weeks (p=0.02), with a 57% remission rate at 3 months following a single dose.2
Helus is not advancing the IV DMT formulation further. Instead, mechanistic insights from SPL026 are informing development of HLP004, a proprietary serotonergic agonist under investigation for generalized anxiety disorder (GAD), with Phase 2 data expected in 2026.
Algernon Pharmaceuticals (renamed Grey Matters Health in April 2026) is investigating AP-188, a sub-psychedelic intravenous DMT infusion for acute ischemic stroke. Their Phase 1 trial showed that a 6-hour IV infusion at sub-psychedelic doses achieved plasma DMT concentrations associated with neuroplasticity in preclinical models, with no safety or tolerability concerns. A 40-patient Phase 2a stroke trial is planned. This is a non-psychedelic medical application — patients would not experience a "trip."
Researchers at Imperial College London, Maastricht University, and UC San Diego have published on DMT pharmacokinetics, subjective effects, and neuroimaging. Imperial's Centre for Psychedelic Research conducted extended-state DMT (DMTx) pilot studies showing that 30-minute IV DMT infusions are safe and well-tolerated in healthy volunteers, with immersion and visual imagery increasing with dose while ego dissolution remained low.6 UC San Diego has a dedicated division for extended-state DMT research. Active trials can be found by searching "DMT" on ClinicalTrials.gov.
If you are searching for DMT near me, the honest answer depends on what you mean. Legal DMT access in the United States — outside of DEA-exempted religious organizations — exists only through authorized clinical trials. Ayahuasca (which contains DMT) is available at DEA-exempted churches in several US states and at retreat centers in Peru, Costa Rica, and Ecuador. Smoked or vaporized freebase DMT has no legal commercial access pathway anywhere in the US outside of clinical research.
"IV DMT retreat" is one of the most common searches that leads to this page — but as of 2026, no commercial retreat center offers intravenous N,N-DMT sessions. IV DMT administration exists only in clinical research settings (see above). Here is what people searching for this term are actually finding, and what the distinctions are:
Intravenous DMT requires medical-grade infusion equipment, continuous hemodynamic monitoring, and clinical staff trained in IV sedation protocols. The IV route also requires pharmaceutical-grade N,N-DMT — not a plant extract. These requirements put IV DMT squarely in the domain of regulated clinical trials, not retreat centers. No jurisdiction has licensed retreat-style IV DMT services.
Retreat centers advertising "DMT" typically offer one of these:
The closest thing to an "IV DMT retreat" in concept is extended-state DMT (DMTx) — a target-controlled IV infusion that maintains a stable psychedelic state for 30 minutes or longer, rather than the 5–15 minutes of a single inhaled dose. This approach was first modeled by Andrew Gallimore and Rick Strassman in 2016 and has since been tested at Imperial College London, where pilot studies with 11 volunteers showed the experience was safe, well-tolerated, and phenomenologically distinct from bolus-dose DMT.6
Extended-state DMT is purely experimental. No retreat center, clinic, or commercial program offers it. If this changes, it will likely emerge first within a regulated clinical trial or — potentially — under Colorado's Prop 122 framework, which includes DMT among natural medicines eligible for future licensed healing centers (no DMT healing centers are operational as of 2026).
As of 2026, legal access pathways in the US are limited:
DMT's short duration when vaporized does not make it medically safe in uncontrolled settings. The acute intensity of the experience can cause significant psychological distress and disorientation, posing injury risks when people are unsupported. Specific contraindications include:
The integration therapy guide covers what post-session support should look like, especially for intense experiences like DMT.
This is one of the most common points of confusion, and the honest answer is: they share the same active compound but are not the same experience. Ayahuasca is a brewed tea that combines a DMT-containing plant (such as Psychotria viridis) with the Banisteriopsis caapi vine, which supplies MAO inhibitors. Those MAOIs are what let DMT survive digestion and become orally active — on its own, swallowed DMT is broken down by the gut before it can take effect. Vaporized or smoked DMT skips that step entirely, delivering the same molecule directly into the bloodstream.
| Factor | Vaporized/smoked DMT | Ayahuasca (oral brew) |
|---|---|---|
| Onset | Seconds to about a minute | 30–60 minutes |
| Duration | 5–20 minutes | 4–6 hours |
| Requires an MAOI? | No — DMT alone is active when vaporized | Yes — the caapi vine's MAOIs are what make oral DMT work at all |
| Intensity / character | Fast, intense, often described as more disorienting given the speed of onset | Slower build, longer integration window within the same session; typically ceremonial, guided context |
| Unique safety risk | Standard DMT safety profile (see below); no MAOI interaction risk | MAOI-drug interactions are the serious added risk — combining ayahuasca with SSRIs, MAOIs, or certain other medications can cause serotonin syndrome (see our medication safety guide) |
| Legal access in the US | Schedule I; no religious-exemption precedent covers smoked/vaporized DMT specifically | Schedule I, but four US religious organizations (UDV, Santo Daime, Iowaska Church of Healing, Church of Gaia) hold confirmed DEA exemptions covering ayahuasca specifically |
In practice, most people asking "DMT vs. ayahuasca" are really choosing between a short, intense, unsupervised-feeling vaporized experience and a longer, ceremony-structured, orally-consumed one — not between two unrelated drugs. See our full ayahuasca guide for ceremony structure, state-by-state legal status, and the MAOI interaction risk in more depth.
All three are serotonergic psychedelics, but their duration, regulatory status, clinical evidence base, and subjective character differ enough that the choice is meaningful — especially for someone weighing clinical trial access or international retreat options.
| N,N-DMT | Psilocybin | 5-MeO-DMT | |
|---|---|---|---|
| Duration | 5–20 min (inhaled); 4–6 h (oral as ayahuasca) | 4–6 h | 15–30 min (inhaled) |
| Primary receptor target | 5-HT2A agonist | 5-HT2A agonist (via psilocin) | 5-HT1A + 5-HT2A (non-selective) |
| Subjective character | Richly visual; narrative; often entity-contact; less all-consuming than 5-MeO-DMT | Visual, emotional, connective; generally the most navigable of the three | Ego-dissolution / "white-out"; less visual; more obliterating |
| Best clinical evidence | Phase 2a IV DMT (SPL026): significant MDD reduction, 2025 | Phase 2b COMP360: −6.6 MADRS vs placebo (2022); multiple Phase 3 underway | Phase 2b GH001: −15.5 MADRS vs placebo, 57.5% remission (2025) |
| US legal access | Schedule I; ayahuasca DEA exemption for 4 religious orgs; Colorado decriminalized possession | Schedule I; Oregon Measure 109 licensed centers (2025+); FDA Breakthrough Therapy designation | Schedule I; FDA clinical hold lifted 2026; Phase 3 planned — no licensed US access yet |
| Psychotherapy required? | IV DMT protocol: no structured therapy required; ayahuasca: ceremonial context | All published trials include structured preparation + integration | GH001: no planned psychotherapy — drug-only protocol tested |
| Verdict | Most accessible via ayahuasca religious exemption; IV route emerging in trials; most visual | Furthest along regulatory path; most clinical infrastructure; best for navigable experience | Strongest single-session remission data; shortest duration; accessible internationally but least regulated |
No. N,N-DMT (dimethyltryptamine) is a Schedule I controlled substance under the federal Controlled Substances Act, where it has been classified since 1970. Possession or distribution carries federal felony penalties. The one significant exception is Colorado, where Prop 122 (2022) decriminalized personal-use possession of DMT for adults 21 and older. In every other state, and under federal law, DMT remains illegal.
No. DMT is Schedule I under California Health & Safety Code §11054. Six California cities — Oakland, San Francisco, Santa Cruz, Berkeley, Arcata, and Eureka — have passed city resolutions directing local police to treat entheogen enforcement as the lowest priority. These resolutions are not legal protections; they do not bind state police or federal prosecutors, and they do not make DMT possession or distribution legal.
Personal-use possession of DMT is decriminalized in Colorado under the Natural Medicine Health Act (Prop 122, 2022) for adults 21 and older. However, no licensed DMT healing centers exist yet — the state's Natural Medicine Advisory Board is expected to address DMT therapeutic access in 2026. Sale and distribution of DMT remain illegal in Colorado, and federal law (Schedule I) still applies statewide.
4-AcO-DMT (psilacetin) is not explicitly listed on the DEA Schedule I list as of 2026. However, the Federal Analogue Act (21 U.S.C. § 813) treats substances 'substantially similar' in structure or pharmacology to a Schedule I drug as Schedule I if possessed for human consumption. Because 4-AcO-DMT is structurally and pharmacologically similar to psilocybin (Schedule I), federal prosecution under the Analogue Act is legally viable. Several states also have their own analogue acts. The 'not for human consumption' label on research-chemical vendors does not provide legal protection for personal use.
N,N-DMT and 5-MeO-DMT are related but pharmacologically distinct compounds. N,N-DMT is primarily a 5-HT2A serotonin receptor agonist and produces a highly visual, relatively long experience when taken as ayahuasca. 5-MeO-DMT is primarily a 5-HT1A agonist and produces a shorter, less visual, more all-consuming ego-dissolution experience when vaporized. Both are Schedule I in the United States.
Ayahuasca contains DMT as its primary psychoactive compound, combined with an MAOI inhibitor (from Banisteriopsis caapi vine) that prevents the DMT from being broken down in the gut. DMT by itself, taken orally without an MAOI, produces no significant psychoactive effects. The MAOI-DMT combination is what creates the 4-6 hour ayahuasca experience. Four US religious organizations hold DEA exemptions to use ayahuasca: the UDV, Santo Daime, Iowaska Church of Healing, and the Church of Gaia.
No. As of 2026, no commercial retreat center anywhere in the world offers intravenous N,N-DMT sessions. IV DMT requires pharmaceutical-grade compound, medical infusion equipment, and continuous hemodynamic monitoring — it exists only in clinical research settings such as Imperial College London's extended-state DMT (DMTx) studies and the Helus Pharma (formerly Small Pharma) depression trials. Retreat centers advertising 'DMT' typically offer ayahuasca (oral, 4–6 hours), 5-MeO-DMT (inhaled, 15–45 minutes), or vaporized N,N-DMT (inhaled, 5–15 minutes) — none of which are administered intravenously.
Extended-state DMT is a research technique using target-controlled intravenous infusion to maintain a stable DMT-induced psychedelic state for 30 minutes or longer, rather than the 5–15 minutes of a single inhaled dose. First proposed by Andrew Gallimore and Rick Strassman in 2016, it has been tested in pilot studies at Imperial College London with 11 volunteers, showing the experience is safe, well-tolerated, and phenomenologically distinct from bolus-dose DMT. UC San Diego also has a dedicated extended-state DMT research program. This technique is purely experimental and is not available outside clinical trials.
Federal personal possession of DMT is a misdemeanor under 21 U.S.C. § 844 for a first offense, carrying up to one year in federal prison and a $1,000 minimum fine. A second personal possession offense increases the maximum to two years. Manufacturing or distributing DMT is a felony under 21 U.S.C. § 841: a conviction for trafficking a Schedule I substance carries up to 20 years in federal prison and a $1 million fine for a first offense, with higher sentences for larger quantities. These federal penalties apply regardless of any state-level decriminalization, including in Colorado.
No. Transporting DMT — including ayahuasca — across US borders is a federal drug importation offense under 21 U.S.C. §§ 952 and 960, regardless of DMT's legal status in the country of origin. A first-offense importation conviction carries up to 20 years in federal prison. Peru's recognition of ayahuasca as traditional cultural heritage and Brazil's legal allowance of ayahuasca for religious use do not create any exemption under US law. Returning travelers have had ayahuasca seized at US customs, and prosecutions have occurred.
There is no legal, standalone "DMT therapy" program available to the public in the United States. The only lawful way to receive DMT in a therapeutic or research context is through an authorized clinical trial — see the "Clinical research on DMT" section above for the active programs (Helus Pharma's SPL026, Algernon/Grey Matters Health's AP-188, and academic extended-state DMT research). Outside of a trial, or membership in one of the four DEA-exempted religious organizations for ayahuasca, administering or receiving DMT remains a Schedule I offense regardless of whether it is framed as "therapy."
No. Unlike LSD — which was legal and used in mainstream psychiatric research from the 1940s until state and then federal bans in the late 1960s and 1970 — DMT has never had a period of US legality. It was placed in Schedule I when the Controlled Substances Act took effect in 1970 and has remained there continuously since.
Get DMT research & policy updates
New trials, FDA decisions, and legal changes for DMT — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.